BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22494588)

  • 21. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
    Dholakia AS; Chaudhry M; Leal JP; Chang DT; Raman SP; Hacker-Prietz A; Su Z; Pai J; Oteiza KE; Griffith ME; Wahl RL; Tryggestad E; Pawlik T; Laheru DA; Wolfgang CL; Koong AC; Herman JM
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):539-46. PubMed ID: 24751410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
    Kim JW; Seong J; Yun M; Lee IJ; Yoon HI; Cho HJ; Han KH
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1172-8. PubMed ID: 21570203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases.
    Howells CC; Stinauer MA; Diot Q; Westerly DC; Schefter TE; Kavanagh BD; Miften M
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e441-6. PubMed ID: 22682809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients.
    Huang YS; Chen JL; Hsu FM; Huang JY; Ko WC; Chen YC; Jaw FS; Yen RF; Chang YC
    J Magn Reson Imaging; 2018 Jan; 47(1):191-199. PubMed ID: 28480541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDG PET uptake as a predictor of pain response in palliative radiation therapy in patients with bone metastasis.
    Adli M; Kuzhan A; Alkis H; Andic F; Yilmaz M
    Radiology; 2013 Dec; 269(3):850-6. PubMed ID: 23985277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation.
    Wang K; Heron DE; Clump DA; Flickinger JC; Kubicek GJ; Rwigema JC; Ferris RL; Ohr JP; Quinn AE; Ozhasoglu C; Branstetter BF
    Radiother Oncol; 2013 Jan; 106(1):90-5. PubMed ID: 23333021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
    Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
    Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Yang Y; Cabrera AR; Sun X; Zhao S; Xie P; Zheng J; Ma L; Fu Z; Yu J
    Dis Esophagus; 2012 Jan; 25(1):54-61. PubMed ID: 21595781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of liver-based standardized uptake value and other quantitative 18F-FDG PET-CT parameters in neoadjuvant therapy response in patients with locally advanced rectal cancer: correlation with histopathology.
    Koç M; Kaya GÇ; Demir Y; Sürücü E; Sarioğlu S; Obuz F; Öztop İ; Görken İB; Sökmen S
    Nucl Med Commun; 2015 Sep; 36(9):898-907. PubMed ID: 25969176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
    Degirmenci B; Wilson D; Laymon CM; Becker C; Mason NS; Bencherif B; Agarwal A; Luketich J; Landreneau R; Avril N
    Nucl Med Commun; 2008 Jul; 29(7):614-22. PubMed ID: 18528183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of ¹⁸F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma.
    Song MJ; Bae SH; Yoo IeR; Park CH; Jang JW; Chun HJ; Choi BG; Lee HG; Choi JY; Yoon SK
    World J Gastroenterol; 2012 Jul; 18(25):3215-22. PubMed ID: 22783045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
    Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of (18)F-fluorodeoxyglucose PET for radiosurgery planning and response monitoring in patients with recurrent spinal metastasis.
    Gwak HS; Youn SM; Chang U; Lee DH; Cheon GJ; Rhee CH; Kim K; Kim HJ
    Minim Invasive Neurosurg; 2006 Jun; 49(3):127-34. PubMed ID: 16921451
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FDG PET/CT early dynamic blood flow and late standardized uptake value determination in hepatocellular carcinoma.
    Bernstine H; Braun M; Yefremov N; Lamash Y; Carmi R; Stern D; Steinmetz A; Sosna J; Groshar D
    Radiology; 2011 Aug; 260(2):503-10. PubMed ID: 21555347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.
    Na F; Wang J; Li C; Deng L; Xue J; Lu Y
    J Thorac Oncol; 2014 Jun; 9(6):834-42. PubMed ID: 24787963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
    Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.